Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib vs sorafenib in first-line advanced hepatocellular carcinoma
CTR20160184Phase 3Completed
- Sponsor
- Suzhou Zelgen Biopharmaceuticals
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of donafenib in hepatocellular carcinoma (HCC), sponsored by Suzhou Zelgen Biopharmaceuticals. Started Apr 2016; status: completed.
02
Drugs
donafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20160184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160184.